Neumora Therapeutics Inc [NASDAQ: NMRA] closed the trading session at $2.93 on 2025-10-30. The day’s price range saw the stock hit a low of $2.67, while the highest price level was $3.045.
The stocks have a year to date performance of -75.27 percent and weekly performance of 26.84 percent. The stock has been moved at 279.83 percent over the last six months. The stock has performed 64.61 percent around the most recent 30 days and changed 87.82 percent over the most recent 3-months.
If compared to the average trading volume of 1.16M shares, NMRA reached to a volume of 7445161 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Neumora Therapeutics Inc [NMRA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NMRA shares is $8.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NMRA stock is a recommendation set at 2.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Neumora Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 27, 2025. The new note on the price target was released on September 16, 2025, representing the official price target for Neumora Therapeutics Inc stock. Previously, the target price had yet another raise to $1, while BofA Securities analysts kept a Underperform rating on NMRA stock.
The Price to Book ratio for the last quarter was 2.59, with the Price to Cash per share for the same quarter was set at 1.34.
NMRA stock trade performance evaluation
Neumora Therapeutics Inc [NMRA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.84. With this latest performance, NMRA shares gained by 64.61% in over the last four-week period, additionally plugging by 279.83% over the last 6 months – not to mention a drop of -72.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NMRA stock in for the last two-week period is set at 75.44, with the RSI for the last a single of trading hit 0.28, and the three-weeks RSI is set at 0.21 for Neumora Therapeutics Inc [NMRA]. The present Moving Average for the last 50 days of trading for this stock 1.84, while it was recorded at 2.67 for the last single week of trading, and 1.40 for the last 200 days.
Neumora Therapeutics Inc (NMRA) Capital Structure & Debt Analysis
According to recent financial data for Neumora Therapeutics Inc. ( NMRA), the Return on Equity (ROE) stands at -89.37%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -80.25%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Neumora Therapeutics Inc’s Return on Invested Capital (ROIC) is -124.38%, showcasing its effectiveness in deploying capital for earnings.
Neumora Therapeutics Inc (NMRA) Efficiency & Liquidity Metrics
Based on Neumora Therapeutics Inc’s (NMRA) latest financial statements, the Debt-to-Equity Ratio is 0.11%, indicating its reliance on debt financing relative to shareholder equity.
Neumora Therapeutics Inc (NMRA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Neumora Therapeutics Inc. (NMRA) effectively leverages its workforce, generating an average of -$2291727.27 per employee. The company’s liquidity position is robust, with a Current Ratio of 10.54% and a Quick Ratio of 10.54%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Neumora Therapeutics Inc [NMRA] stock
With the latest financial reports released by the company, Neumora Therapeutics Inc posted -0.45/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.07. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NMRA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Neumora Therapeutics Inc go to 12.12%.
Neumora Therapeutics Inc [NMRA]: Institutional Ownership
There are presently around $53.65%, or 74.03%% of NMRA stock, in the hands of institutional investors. The top three institutional holders of NMRA stocks are: FMR LLC with ownership of 8.62 million shares, which is approximately 5.4235%. SOFTBANK GROUP CORP., holding 7.65 million shares of the stock with an approximate value of $$75.17 million in NMRA stocks shares; and SOFTBANK GROUP CORP., currently with $$50.14 million in NMRA stock with ownership which is approximately 3.2086%.
